Taken together, our pre-clinical findings demonstrate the safety of Fontup® on hepatic and cardiac functions, and normalization of relevant plasma and neuronal biomarkers in mice overexpressing Dyrk1A. These results guide the dose to be used in future clinical studies both in adults and children with DS. The gene discussed is DYRK1A; the disease is Dravet syndrome.